Rubicon Research Ltd. Share Price

Overview

Rubicon Research Ltd. share price is currently ₹1,788.08, up by ₹96.45 (5.7%) from its previous closing price of ₹1,691.63. The share price has gained 18.2% over the past month and gained 7.32% over the past year. The stock's 52-week low and high are ₹570.75 and ₹1,806.91, respectively. Rubicon Research Ltd. has a market capitalisation of ₹ 28,550.00 Cr. The share price was last updated on 26 Aug 2026, 03:54 PM IST.

Rubicon Research Ltd.
Rubicon Research Ltd.
RUBICON
 0.00
 96.45
5.70%
Miscellaneous
 0.00(%)1D

Updated: 26 Aug 2026, 03:54:41 pm IST

Market Data

Open Price

 1,666.13

Prev. Close

 1,691.63
 1,666.13

Day Low

 1,798.58

Day High

 570.75

52 Week Low

 1,806.91

52 Week High

MiscellaneousMiscellaneous
CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

101.14

Sector PE

98.43

PB Ratio

23.47

Sector PB

7.07

EPS

17.68

Dividend Yield

0.19

Today's Volume

739.561 K

5 Day Avg. Volume

416.337 K

PEG Ratio

1.42

Market Cap.

₹ 28,550.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 150% at ₹1.5/Share
07-Aug-202607-Aug-2026

Mutual Fund Ownership

Mutual Fund Holder
Jun 26
Shares held
Jul 26
Shares held
Kotak Midcap Fund - Regular Plan - Growth37.78 Lac
37.78 Lac
no change
Motilal Oswal Small Cap Fund - Regular Plan - Growth22.58 Lac
22.58 Lac
no change
Bajaj Finserv Flexi Cap Fund - Regular Plan - Growth10.47 Lac
10.06 Lac
(3.95%)
Kotak Manufacture in India Fund - Regular Plan - Growth8.33 Lac
8.33 Lac
no change
Bajaj Finserv Small Cap Fund - Regular Plan - Growth6.59 Lac
6.48 Lac
(1.68%)

About Rubicon Research Ltd. 👋

Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Ashish Kumar

Ashish Kumar

26 Aug • 3:42 PM · SEBI-Registered Analyst

Block Deals Spotlight: PhysicsWallah and Rubicon

Shares of PhysicsWallah surged as much as 5% on Wednesday after nearly 4.67 crore shares, representing around 1.6% of the company’s equity, changed hands in multiple block deals valued at approximately Rs 550 crore. The transactions were executed at Rs 117.72 per share, a roughly 3% discount to the previous close of Rs 121. Despite the discounted price, the stock climbed sharply in early trade, touching an intraday high near Rs 127-128. Buyers and sellers in the deals have not been disclosed. As of the end of the June quarter, promoter entities held about 71% stake, with public shareholders owning the remaining 29%. The activity comes amid a strong recovery for the edtech stock, which has risen over 40-60% from its March 2026 low of Rs 77.72. It also follows PhysicsWallah’s Q1 FY27 results, where consolidated revenue grew about 24% year-on-year to Rs 1,054 crore and net loss narrowed significantly. Separately,

RUBICON
esearch saw around 8.4 lakh shares change hands in a block deal worth Rs 140 crore, executed near Rs 1,660 per share. The pharma stock rose as much as 4-6% in response, continuing its strong performance this year. Buyers and sellers in both transactions remain undisclosed. Promoters hold majority stakes in both firms—about 71% in PhysicsWallah and around 60% in Rubicon. These large deals highlight continued investor interest in select mid- and small-cap names amid broader market activity.

See More
Saurabh Tyagi--Clovek,Advisory

Saurabh Tyagi--Clovek,Advisory

20 Aug • 3:53 PM · SEBI-Registered Analyst

RUBICON
announced Q1FY27 results Consolidated Financial Highlights:

RUBICON
announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The company reported revenue of Rs 5,343.38 million in Q1FY27, representing a YoY growth of 51.59% compared to Rs 3,524.94 million in Q1FY26 and a QoQ growth of 3.97% from Rs 5,139.15 million in Q4FY26. Total Income: Total income for Q1FY27 stood at Rs 5,400.21 million, increasing by 52.92% YoY from Rs 3,531.27 million and by 4.55% QoQ from Rs 5,165.25 million. Net Profit after Tax: The company achieved a Net Profit of Rs 847.81 million in Q1FY27, a significant increase of 95.79% YoY from Rs 433.01 million. On a QoQ basis, profit grew by 10.41% from Rs 767.85 million in Q4FY26. Total Comprehensive Income: Total comprehensive income for the quarter was Rs 800.49 million in Q1FY27 compared to Rs 504.18 million in Q1FY26 and Rs 827.39 million in Q4FY26. Earnings Per Share (EPS): Basic EPS grew to Rs 5.13 in Q1FY27 from Rs 2.81 in Q1FY26. Diluted EPS stood at Rs 5.08 compared to Rs 2.79 in the same period last year.

See More
Akhilesh Jat SEBI RA

Akhilesh Jat SEBI RA

17 Aug • 9:22 AM · SEBI-Registered Analyst

Rubicon Research Hits Fresh All-Time High on Blockbuster Q1 Show

Rubicon Research [

RUBICON
] rallied up to 9.92% in morning trade, hitting a fresh all-time high of Rs 1,779.70, after posting a strong Q1 FY27 show. Consolidated net profit spiked 95.8% YoY to Rs 84.8 crore from Rs 43.3 crore, while revenue jumped 51.6% YoY to Rs 534.3 crore from Rs 352.5 crore. Profit growth nearly double the pace of revenue growth signals strong operating leverage and margin expansion, a healthy sign for a pharma/specialty business scaling output. The all-time-high breakout reflects strong market conviction in this earnings momentum. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More
SASI KUMAR SEBI RA

SASI KUMAR SEBI RA

26 Jul • 8:50 AM · SEBI-Registered Analyst

While most stocks are still struggling below their highs...

A few are quietly making fresh All-Time Highs. 👀 Large Cap ✓ Bajaj Auto ✓ Titan ✓ Federal Bank Mid & Small Cap ✓ Lloyds Metals & Energy ✓ Laurus Labs ✓ Rubicon Research ✓ Diamond Power Infrastructure ✓ SJS Enterprises Stocks making new ATHs while the broader market remains weak are worth keeping on your watchlist.

See More
Akhilesh Jat SEBI RA

Akhilesh Jat SEBI RA

23 Jul • 8:35 AM · SEBI-Registered Analyst

Stocks in Focus: Key Corporate Developments May Drive Attention

HCL Technologies:

HCLTECH
has been chosen by TIM Brasil, the country’s 5G leader, to enable South America’s first cross-platform eSIM transfer capability. The initiative is aimed at simplifying the mobile experience for millions of users in Brazil and marks another milestone in the company’s digital transformation and telecom technology capabilities. Rubicon Research:
RUBICON
has expanded its global manufacturing presence through the acquisition of a manufacturing facility in East Brunswick, New Jersey, from InvaTech Pharma Solutions for an enterprise value of $2.9 million. The transaction provides the company with a strategic manufacturing footprint in the United States. Sona BLW Precision Forgings (
SONACOMS
) : The company has entered into definitive agreements with Japan’s DENSO Corporation to form two joint ventures focused on advanced electric and hybrid powertrain systems, strengthening its presence in the evolving mobility and automotive technology ecosystem. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More
PATEL ABHIKUMAR HARESHBHAI

PATEL ABHIKUMAR HARESHBHAI

3 Jun • 12:25 PM · SEBI-Registered Analyst

Daily Index View : NIFTY50 as on 03/06/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -20% 🔍 Key Level to Watch: 23821 🔄 Current Market Surface: The trend will stay Positive until the market stay above 23821 That’s 438 points away from the last day Closing Price of 23383 ATR 338 2. Demand & Supply PROBABILITY Force is Demand & Supply is Modarate -10% Last 3 days market has fallen, but not too much compared to ATR, so supply has good firepower 02 Jun 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) -8,363 +9,589.32 3. Reflexivity PROBABILITY First Half is Supportive to Bearish Momentum for at least first half -10% Last day market fell Intraday more than the 8-day average ATR, so downside momentum should remain intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 395 -26% Dow jones future (live) 51,312 Up/Donw by -88 Hang seng (Live) 26038 Up/Donw by -440 Nikki 225 (Live) 68588 Up/Donw by 1,853 Sentiments: Dow Jones Futures is Trading Flat to Negative & HANG SENG Index is trading Extremely Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias Top stock to watchout

RUBICON

See More

News & Events

Frequently Asked Questions

What is the share price of Rubicon Research Ltd.?

What is the market cap of Rubicon Research Ltd.?

Should I buy Rubicon Research Ltd. stock now?

What is the 52 week high and low of Rubicon Research Ltd.?

Is the Rubicon Research Ltd. stock good to buy?

Is Rubicon Research Ltd. a good buy for the long term?

Is Rubicon Research Ltd. overvalued or undervalued?

What is the PE and PB ratio of Rubicon Research Ltd.?

Start Now